Cannabidiol
- Generic Name
- Cannabidiol
- Brand Names
- Epidiolex, Sativex, Epidyolex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H30O2
- CAS Number
- 13956-29-1
- Unique Ingredient Identifier
- 19GBJ60SN5
- Background
Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...
- Indication
When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...
- Associated Conditions
- Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain
- Associated Therapies
- -
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
- Conditions
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2023-12-01
- Target Recruit Count
- 9
- Registration Number
- NCT03467113
- Locations
- 🇺🇸
PANDA Neurology/CIRCA, Atlanta, Georgia, United States
🇺🇸MultiCare Institute for Research & Innovation, Tacoma, Washington, United States
Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam
- Conditions
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 42
- Registration Number
- NCT03398083
- Locations
- 🇺🇸
Debra Kelsh, MD, Overland Park, Kansas, United States
Cannabidiol as an Adjunctive Treatment for Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 36
- Registration Number
- NCT03310593
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Cannabidiol as a Treatment for AUD Comorbid With PTSD
- Conditions
- Interventions
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 95
- Registration Number
- NCT03248167
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)
- Conditions
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 75
- Registration Number
- NCT03215940
- Locations
- 🇺🇸
University Of Utah, Salt Lake City, Utah, United States
Population Pharmacokinetics of Antiepileptic in Pediatrics
- Conditions
- Interventions
- Biological: Valproic acidBiological: carbamazepineBiological: phenobarbitalBiological: phenytoinBiological: levetiracetamBiological: lamotrigineBiological: topiramateBiological: oxcarbazepineBiological: stiripentolBiological: clobazamBiological: brivaracétamBiological: felbamateBiological: lacosamideBiological: rufinamideBiological: gabapentineBiological: pregabalineBiological: sultiameBiological: tiagabineBiological: vigabatrineBiological: mesuximideBiological: primidoneBiological: perampanelBiological: ethosuximideBiological: zonisamideBiological: cannabidiolOther: genetic polymorphisms
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1000
- Registration Number
- NCT03196466
- Locations
- 🇫🇷
AP-HP Cochin, Paris, France
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03102918
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Study of Cannabidiol for Drug-Resistant Epilepsies
- Conditions
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Eric Marsh, MD
- Registration Number
- NCT03014440
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 32
- Registration Number
- NCT02932605
- Locations
- 🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands
Cannabidiol and Emotional Stimuli
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 38
- Registration Number
- NCT02902081
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.